Navigation Links
Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use
Date:5/24/2011

RARITAN, N.J., May 24, 2011 /PRNewswire/ -- Veridex, LLC today announced the launch of the CELLTRACKS® Circulating Melanoma Cell (CMC) kit, providing research scientists with a fast, convenient and reliable way to capture CMCs for research studies. Using proprietary immunomagnetic technology to capture and count CMCs, the CELLTRACKS® CMC kit is designed to offer data that support researchers engineering investigational therapies that are based on a specific protein or mutation.

"The CELLTRACKS® CMC kit is an essential research tool to enable melanoma cell capture for the oncology community," said Mark Connelly, Ph.D., Director of Cellular Research & Development for Veridex and co-author of the study Circulating Melanoma Cells and Survival in Metastatic Melanoma published in the January 2011 edition of the International Journal of Oncology. "Current methods of melanoma cell capture, such as biopsy and polymerase chain reaction (PCR), are time intensive. This new kit will automate the process, making it simple and reproducible."

The CELLTRACKS® CMC kit is an innovative enabling technology for using biomarkers to identify and enumerate CMCs, melanoma cells that have detached from tumors and entered the blood stream. Based on the same immunomagnetic technology that powers Veridex's CELLSEARCH® technology, researchers can use the kit to capture CMCs and then select a protein biomarker of their choosing to further refine their research. The technology used in the CELLSEARCH® System to capture and count circulating tumor cells (CTCs) was ranked as the top medical innovation for 2009 by the Cleveland Clinic, a leading multispecialty academic medical center and honored with the prestigious Prix Galien USA Award for "Best Medical Technology."

About Circulating Melanoma Cells

The CMC kit is intended for research use only. Performance characteristics have not been established. In 2010, 84 melanoma clinical trials were initiated, bringing the total of active melanoma studies to 515. For more information including annual patient impact statistics, please visit the American Cancer Society.

About Veridex Clinical Research Solutions

Veridex Clinical Research Solutions (CRS) is a leading scientific research organization that pioneers tools and services that may be used for the selection, identification and enumeration of targeted rare cells in peripheral blood for the identification of biomarkers, aiding scientists in their search for new, targeted therapies. Veridex pioneered the automated detection, capture and enumeration of CTCs more than a decade ago and continues to lead with industry firsts with the introduction of the first Circulating Endothelial Cell kit in 2007 and the introduction of the first CMC kit in 2011.

Veridex CRS creates customizable research approaches that allow real-time biopsy and re-interrogation of rare cells, enabling researchers to study their genetic makeup in the search for biomarkers and new, targeted therapies. Veridex clinical research products are ready-to-use reagents and supplies that may be used for the immunomagnetic selection, identification and enumeration of targeted cells in peripheral blood for the identification of biomarkers. Veridex CRS' innovations may help optimize the efficiency of clinical trials and accelerate drug development programs at all phases of clinical trial testing, ranging from pre-clinical research to biomarker assay development and market launch.

About Veridex, LLC

Veridex, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value diagnostic oncology products. Veridex's in vitro diagnostic products may significantly benefit patients by helping physicians make more informed decisions that enable better patient care. For more information, visit www.veridex.com


'/>"/>
SOURCE Veridex, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Veridex, LLC Announces Collaboration to Develop Next-Generation Circulating Tumor Cell (CTC) Technology with Massachusetts General Hospital
2. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
3. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
4. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
5. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
6. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
7. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
8. Premier Micronutrient Launches Supplement for Hearing Health
9. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
10. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
11. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24. Februar 2017 ITL Limited, ( ... Gesundheitsbereiches, ist erfreut, für das zum 31. Dezember ... Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine vollständige ... Wachstum" finden Sie hier . ... Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... Feb. 23, 2017  This report analyzes the worldwide ... following Products: Intermediates, Analytical, and Others. ... include Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive ... Europe , and Rest of World. ... 2015 through 2022. Also, a six-year historic analysis is ...
(Date:2/24/2017)... Medivir AB (Nasdaq Stockholm: MVIR) today announced ... Directors that will be submitted to the 2017 Annual ... the company,s three largest shareholders at the end of ... seat on the Nomination Committee, and the Chairman of ... was as follows:  Anders ...
Breaking Medicine Technology:
(Date:2/24/2017)... Melbourne, Australia (PRWEB) , ... February 24, 2017 , ... ... Press AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema ... post-traumatic stress disorder and his attempts to overcome them. , Schanssema, initially unsure ...
(Date:2/24/2017)... ... 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer ... started as the Chairman of the Management Committee when IFN was originally formed in ... recruitment of investor/owners and development of the business plan. He became the first ...
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... Chapel Hill, NC (PRWEB) , ... February 23, 2017 , ... ... the Platinum Sponsor for ACPA’s 74th Annual Meeting. KLS is a longtime supporter ... in 2017 as an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... on “Doping in Sport: How the Culture Might Change,” in conjunction ... The symposium will be held at Pepperdine University in Malibu, California. , Sir ...
Breaking Medicine News(10 mins):